267 related articles for article (PubMed ID: 21694929)
1. Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients.
Nodari S; Jao GT; Chiong JR
Int J Nephrol Renovasc Dis; 2010; 3():51-60. PubMed ID: 21694929
[TBL] [Abstract][Full Text] [Related]
2. [Vasopressin antagonists in treatment of hyponatremia].
Olszewski W; Głuszek J
Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
[TBL] [Abstract][Full Text] [Related]
3. Hyponatremia, heart failure, and the role of tolvaptan.
O'Connell JB; Alemayehu A
Postgrad Med; 2012 Mar; 124(2):29-39. PubMed ID: 22437213
[TBL] [Abstract][Full Text] [Related]
4. Vaptans and hyponatremia in critical patients.
D'Auria D; Marinosci GZ; De Benedictis G; Piazza O
Transl Med UniSa; 2012 May; 3():1-14. PubMed ID: 23905047
[TBL] [Abstract][Full Text] [Related]
5. Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.
Gaglio P; Marfo K; Chiodo J
Dig Dis Sci; 2012 Nov; 57(11):2774-85. PubMed ID: 22732834
[TBL] [Abstract][Full Text] [Related]
6. Vasopressin receptor antagonists and their role in clinical medicine.
Narayen G; Mandal SN
Indian J Endocrinol Metab; 2012 Mar; 16(2):183-91. PubMed ID: 22470853
[TBL] [Abstract][Full Text] [Related]
7. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
[TBL] [Abstract][Full Text] [Related]
8. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
Lin TE; Adams KF; Patterson JH
Heart Fail Clin; 2014 Oct; 10(4):607-20. PubMed ID: 25217436
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
10. Vaptans for the treatment of hyponatremia.
Robertson GL
Nat Rev Endocrinol; 2011 Mar; 7(3):151-61. PubMed ID: 21283124
[TBL] [Abstract][Full Text] [Related]
11. Hyponatremia in Heart Failure: Pathogenesis and Management.
Rodriguez M; Hernandez M; Cheungpasitporn W; Kashani KB; Riaz I; Rangaswami J; Herzog E; Guglin M; Krittanawong C
Curr Cardiol Rev; 2019; 15(4):252-261. PubMed ID: 30843491
[TBL] [Abstract][Full Text] [Related]
12. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
Vaghasiya RP; DeVita MV; Michelis MF
Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms, risks, and new treatment options for hyponatremia.
Ghali JK
Cardiology; 2008; 111(3):147-57. PubMed ID: 18434717
[TBL] [Abstract][Full Text] [Related]
14. Unpredictable nature of tolvaptan in treatment of hypervolemic hyponatremia: case review on role of vaptans.
Malhotra I; Gopinath S; Janga KC; Greenberg S; Sharma SK; Tarkovsky R
Case Rep Endocrinol; 2014; 2014():807054. PubMed ID: 24511399
[TBL] [Abstract][Full Text] [Related]
15. Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure.
Vinod P; Krishnappa V; Chauvin AM; Khare A; Raina R
Cardiol Res; 2017 Jun; 8(3):87-95. PubMed ID: 28725324
[TBL] [Abstract][Full Text] [Related]
16. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
[TBL] [Abstract][Full Text] [Related]
17. Vaptans: a promising therapy in the management of advanced cirrhosis.
Ginès P
J Hepatol; 2007 Jun; 46(6):1150-2. PubMed ID: 17445935
[TBL] [Abstract][Full Text] [Related]
18. Clinical review: the use of vaptans in clinical endocrinology.
Peri A
J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044
[TBL] [Abstract][Full Text] [Related]
19. V2 receptor antagonist; tolvaptan.
Yi JH; Shin HJ; Kim HJ
Electrolyte Blood Press; 2011 Dec; 9(2):50-4. PubMed ID: 22438856
[TBL] [Abstract][Full Text] [Related]
20. Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
Farmakis D; Filippatos G; Kremastinos DT; Gheorghiade M
Curr Heart Fail Rep; 2008 Jun; 5(2):91-6. PubMed ID: 18765079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
